Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

Mar 22, 2018

Overview : Trial Reference White WB, Saag KG, Becker MA, et al; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 12. doi: 10.1056/NEJMoa1710895. [Epub ahead of print] Abstract | Full Text   Expert Comment... more

6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial

Mar 20, 2018

Overview : Trial Reference Hahn JY, Song YB, Oh JH, et al; SMART-DATE investigators. 6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial. Lancet. 2018 Mar 9.... more

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Sep 06, 2017

Overview : Trial Reference Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 Aug 27 [Epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas,... more

ODYSSEY Long Term Study

Oct 15, 2014

Overview : The Odyssey Long Term Study evaluated the safety and efficacy of alirocumab (mAb anti-PCSK9) in 2341 patients with heterozygous FH or at high risk for cardiovascular events who were receiving a maximally tolerated dose of statin but who had an... more

: PARADIGM-HF. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Oct 15, 2014

Overview : The the novel agent LCZ696 (Novartis) that has effects both within and beyond the renin-angiotensin system, was tested against of the ACE inhibitor enalapril, showing fewer HF hospitalizations and mortality from cardiovascular causes, acccording a phase 3 trial PARADIGM-HF. In... more

STREAM-Strategic Reperfusion With Tenecteplase and Antithrombotic Treatment Early After Myocardial Infarction

Jul 17, 2014

Overview : This trial confirmed that fibrinolysis with tenecteplase and contemporary antithrombotic therapy given before transport to a PCI-capable hospital, coupled with timely coronary angiography, is as effective as primary PCI in STEMI patients presenting within 3 hours of symptom onset who... more

RELAX TRIAL: Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Jul 17, 2014

Overview : RELAX-AHF was an international, double-blind, placebo-controlled trial, enrolling patients admitted to hospital for acute heart failure who were randomly assigned (1:1) via a central randomisation scheme blocked by study centre to standard care plus 48-h intravenous infusions of placebo or... more

PARAMOUNT: Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction

Jul 17, 2014

Overview : The result showed that levels of NT-proBNP dropped 23% (p=0.005) over 12 weeks but only by 15% (p=0.20) over 36 weeks among those receiving LCZ696 compared with valsartan. LCZ696 was effective for the primary [natriuretic-peptide] end point in every single... more

LAPLACE-2 TRIAL

Jul 17, 2014

Overview : This is the (proprotein convertase subtilisin-kexin type 9) PCSK9 monoclonal-antibody inhibitor that increases the ability of the liver to clear low-density-lipoprotein cholesterol (LDL-C). According to results of the LAPLACE-2 trial -presented on March 30 during the ACC 2014 in Washington,... more

CHAMPION-PHOENIX: A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention

Jul 17, 2014

Overview : The study randomized over 11,000 patients and the result showed that intravenous cangrelor cut the risk for periprocedural complications at all kinds of PCI compared with taking a pill of clopidogrel. Cangrelor's benefit of a 22% drop in a composite... more

Page: